drugset
Drugs / REZATOMIDINE
last change Feb 2008 re-read 3 minutes ago

REZATOMIDINE

also known as AGN 203818 · AGN-203818 FREE BASE · Rezatomidina

Small molecule

Developed for
diabetic neuropathy · fibromyalgia · interstitial cystitis · irritable bowel syndrome
Investigated by
Allergan

Trials 4

today NCT00441766 · Ph 2 NCT00445705 · Ph 2 NCT00381719 · Ph 2 NCT00380783 · Ph 2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00441766 Mar 2007 → Feb 2008 irritable bowel syndrome Allergan Terminated No outcome recorded
Phase 2 NCT00445705 Mar 2007 → Jan 2008 fibromyalgia Allergan Terminated No outcome recorded
Phase 2 NCT00381719 Oct 2006 → Nov 2007 diabetic neuropathy Allergan Completed No outcome recorded
Phase 2 NCT00380783 Oct 2006 → Mar 2007 interstitial cystitis Allergan Terminated No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as REZATOMIDINE ChEMBL registry synonym — accepted as the source's own label CHEMBL2107366 ↗
Known as AGN 203818 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00380783 ↗
3

NCT00445705 ↗

NCT00441766 ↗

NCT00381719 ↗
Known as AGN-203818 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL2107366 ↗
Known as Rezatomidina ChEMBL registry synonym — accepted as the source's own label CHEMBL2107366 ↗
Modality Small molecule — CHEMBL2107366 ↗
Route Oral “Oral AGN 203818” NCT00441766 ↗